[July 28, 2015]

Research and Markets: Gliosarcoma Pipeline Review H1 2015 - Analysis of 7 Companies & 11 Drug Profiles

Research and Markets (http://www.researchandmarkets.com/research/62p2ff/gliosarcoma) has announced the addition of the "Gliosarcoma - Pipeline Review, H1 2015" report to their offering.

This report provides comprehensive information on the therapeutic development for Gliosarcoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Gliosarcoma and special feature on late-stage and discontinued projects.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Companies Involved in Therapeutics Development

• Amgen Inc.
• Burzynski Research Institute, Inc.
• Celgene Corporation
• Merck & Co., Inc.
• Millennium Pharmaceuticals, Inc.
• NewLink Genetics Corporation
• Sanofi

Drug Profiles

• alisertib
• Antineoplaston Therapy
• CC-122
• DNX-2401
• indoximod
• lonafarnib
• Oncolytic Virus to Target (News - Alert) IL-12 for Oncology
• plerixafor
• rilotumumab
• SGT-53
• Stem Cell Therapy for Glioma

For more information visit http://www.researchandmarkets.com/research/62p2ff/gliosarcoma

View source version on businesswire.com: http://www.businesswire.com/news/home/20150728006284/en/

[ Back To TMCnet.com's Homepage ]